Pharmaceutical

Sionna raises $182m to double down in cystic fibrosis drug development

Sionna could have four candidates in clinical trials in 2024, amidst a cystic fibrosis landscape that is dominated by Vertex.

Mar 7, 2024 - 18:00
Sionna raises $182m to double down in cystic fibrosis drug development
Sionna could have four candidates in clinical trials in 2024, amidst a cystic fibrosis landscape that is dominated by Vertex.
Read the original article

Tags:

Previous Article

Citius aims to bounce back from Lymphir setback

Next Article

Merck reports drop in net income for fiscal 2023

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Cambridge biotech Thymmune wins $37m NIH grant for thymic cell therapies

Cambridge biotech Thymmune wins $37m NIH grant for thym...

Sep 29, 2023

FDA approves J&J’s OPSYNVI for pulmonary arterial hypertension

FDA approves J&J’s OPSYNVI for pulmonary arterial hyper...

Mar 26, 2024

Q2 2024 update: electronic medical record (emr) systems related private equity activity in the pharmaceutical industry

Q2 2024 update: electronic medical record (emr) systems...

Aug 7, 2024